South Africa Seeks Gilead Lenacapavir Manufacturing

South African officials are collaborating with international partners, including Unitaid and the United States Pharmacopoeia, to identify domestic manufacturers for Gilead Sciences' lenacapavir, a groundbreaking HIV prevention injection. This initiative aims to expand access to the drug in South Africa, which has 8 million people living with HIV, and across the African continent. Gilead Sciences has previously granted six manufacturing licenses to producers in India, Egypt, and Pakistan, allowing them to supply 120 developing nations. However, no South African companies were included in these initial agreements. Gilead Sciences has expressed openness to additional partnerships in Sub-Saharan Africa, provided quality standards are met. Leaders like Paul Mashatile of South Africa and William Ruto of Kenya emphasize the importance of local production for regional self-reliance and improved health outcomes. This move could address the anticipated demand exceeding supply until generic manufacturers begin production and potentially expand access to middle-income nations currently excluded from existing licenses.